Thrivent Financial for Lutherans’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,367	Closed	-$14K	–	2550
2022 Q1	$14K	Buy	1,367 +208	+18%	+$2.25K	﹤0.01%	2492
2021 Q4	$50K	Hold	1,159	–	–	﹤0.01%	2452
2021 Q3	$50K	Hold	1,159	–	–	﹤0.01%	2463
2021 Q2	$50K	Hold	1,159	–	–	﹤0.01%	2443
2021 Q1	$57K	Buy	1,159 +675	+139%	+$37.1K	﹤0.01%	2513
2020 Q4	$17K	Buy	+484	New	+$15.2K	﹤0.01%	2461

Other funds holding FRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Thrivent Financial for Lutherans's FRTX Position: Q2 2022 in Review

Thrivent Financial for Lutherans sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2022, closing a stake of 1,367 shares — an estimated $14K sold.

Thrivent Financial for Lutherans first reported a position in FRTX in Q4 2020 and held it in 6 quarters. The position peaked at $57K in Q1 2021. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2022.

Thrivent Financial for Lutherans reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Thrivent Financial for Lutherans sold 1,367 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $14K.
Thrivent Financial for Lutherans first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Thrivent Financial for Lutherans's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $57K in Q1 2021.
22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2022, filed 16 Aug 2022.